MFDS designates renal cell carcinoma therapy ‘cabozantinib’ as orphan drug
‘Cabozantinib,’ a progressive renal cell carcinoma treatment, will be designated as orphan drug.
The Ministry of Food and Drug Safety(MFDS) will make a pre-announcement of the ‘Partial Amendment to the Regulation for Designation of Orphan Drugs’ on the 6th, and said it will additionally designat...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
